The Board of Directors of Affymax, Inc. (OTCPK:AFFY) is reviewing its strategic options as a result of the termination of the collaboration with Takeda Pharmaceutical Company Limited (TSE:4502). Affymax and Takeda would terminate their Omontys product partnership in September. The firms would also withdraw their new drug application with the U.S. Food and Drug Administration.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0008 USD | +6.67% | 0.00% | +33.33% |
1st Jan change | Capi. | |
---|---|---|
+33.33% | 59.59K | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- AFFY Stock
- News Affymax, Inc.
- Affymax To Review Strategic Options